Is It Too Late to Buy Johnson & Johnson After Its Blowout Earnings Report?
2026-07-19 22:10
•Adria Cimino •The Motley Fool
•••••• •• Axe Capital view
J&J’s Earnings Shine, But What About Local Investors?
Johnson & Johnson’s strong earnings highlight steady pharma growth, yet South African investors must weigh local currency and valuation factors.
Johnson & Johnson’s recent earnings report is undeniably impressive. Revenue rose 6% to $25 billion, led by blockbuster drug growth—Darzalex up 18%, Tremfya up 72%—and the company bumped up its full-year revenue guidance. J&J’s diversified portfolio, with more than 28 billion-dollar products and a 50-year dividend growth streak, makes it a solid choice for those chasing steady income. But for South African investors, the picture is less straightforward. The rand’s ongoing volatility versus the dollar means returns in ZAR can swing widely even when the underlying stock looks solid. Also, J&J now trades near all-time highs, limiting margin for error. If the USD/ZAR weakens suddenly, your gains could fade quickly. This isn’t a call to avoid the stock entirely—just a reminder that patience might pay off. Wait for better entry points, especially if the rand spikes stronger. this is just my opinion and not financial advice
Watch USD/ZAR closely before adding J&J exposure. Consider buying on dips around forex strength or valuation pullbacks, rather than chasing the current rally.
- JNJ
- USD/ZAR
- Rand volatility eroding dollar returns
- Stock trading near peak valuation leaves limited upside
6/10
Johnson & Johnson delivered strong earnings with revenue growth of 6% to $25 billion and raised full-year guidance to $101.1 billion. Key drugs like Darzalex (up 18%) and Tremfya (up 72%) offset Stelara declines. While the stock has gained 22% this year and trades near valuation highs, the company's broad portfolio of 28+ blockbuster products and 50+ years of dividend increases make it attractive for long-term and dividend-focused investors, though value investors may wait for a better entry point.
This article was originally published by The Motley Fool and has been adapted here for Axe Capital Trading News.
Publisher: The Motley Fool
Author: Adria Cimino
Categories: Equities, Earnings, Capital Returns, Forex, Consumer, Retail
Tickers: JNJ, KVUE
Sentiment: Positive - Strong blowout earnings with 6% revenue growth, raised full-year guidance, key drugs showing significant growth (Darzalex +18%, Tremfya +72%), diversified portfolio of 28+ billion-dollar products, and 50+ years of consecutive dividend increases demonstrate solid fundamentals and long-term growth potential. Mentioned as the spinoff of J&J's consumer health business. While the spinoff was strategic for J&J to focus on higher-growth pharmaceuticals and medtech, the article provides no specific performance data or outlook for Kenvue itself.
Keywords: earnings report, pharmaceutical, medical devices, dividend growth, valuation, blockbuster drugs, revenue guidance
Insights:
- JNJ: Positive: Strong blowout earnings with 6% revenue growth, raised full-year guidance, key drugs showing significant growth (Darzalex +18%, Tremfya +72%), diversified portfolio of 28+ billion-dollar products, and 50+ years of consecutive dividend increases demonstrate solid fundamentals and long-term growth potential.
- KVUE: Neutral: Mentioned as the spinoff of J&J's consumer health business. While the spinoff was strategic for J&J to focus on higher-growth pharmaceuticals and medtech, the article provides no specific performance data or outlook for Kenvue itself.